Last reviewed · How we verify
pemetrexed plus cisplatin or carboplatin — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
pemetrexed plus cisplatin or carboplatin (pemetrexed plus cisplatin or carboplatin) — Anhui Provincial Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| pemetrexed plus cisplatin or carboplatin TARGET | pemetrexed plus cisplatin or carboplatin | Anhui Provincial Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- pemetrexed plus cisplatin or carboplatin CI watch — RSS
- pemetrexed plus cisplatin or carboplatin CI watch — Atom
- pemetrexed plus cisplatin or carboplatin CI watch — JSON
- pemetrexed plus cisplatin or carboplatin alone — RSS
Cite this brief
Drug Landscape (2026). pemetrexed plus cisplatin or carboplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/pemetrexed-plus-cisplatin-or-carboplatin. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab